Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESCARTES: Evolocumab Long-Term Efficacy in Hyperlipidemia
NCT01516879Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2012
- Primary completion
- Oct 2013
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Evolocumab with Placebo (2 arms). Primary endpoint: Percent Change From Baseline in LDL-C at Week 52. Started Jan 2012; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01516879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01516879.